Parse Biosciences, a subsidiary of QIAGEN N.V., has made its Evercode™ Whole Transcriptome FFPE kits available for purchase and shipping to customers as of March 31, 2026.
The kits enable true whole‑transcriptome single‑cell RNA sequencing from formalin‑fixed, paraffin‑embedded (FFPE) samples, a sample type that has long been difficult to analyze at single‑cell resolution. By adding FFPE compatibility, Parse expands QIAGEN’s single‑cell sequencing platform into a widely used archival specimen, allowing researchers in cancer, neuroscience, and translational science to interrogate archived tissues at the single‑cell level.
The launch follows QIAGEN’s 2025 acquisition of Parse for an upfront payment of $225 million and potential milestone payments of up to $55 million. The integration is expected to contribute roughly $40 million to QIAGEN’s 2026 revenue and to become accretive to earnings from 2028 onward. The Evercode platform’s ability to work with FFPE samples positions QIAGEN to capture a share of the projected single‑cell market, which is projected to grow from $1.2 billion in 2024 to $2.1 billion by 2029 at a 10% annual growth rate.
The new kits open a significant tailwind for QIAGEN, as they allow laboratories that routinely handle archived specimens to adopt single‑cell analysis without the need for fresh tissue. This capability is expected to broaden QIAGEN’s customer base, create a new revenue channel, and strengthen its competitive advantage against other single‑cell providers that lack FFPE compatibility.
The launch aligns with QIAGEN’s broader strategy to accelerate AI‑driven drug discovery. By integrating Parse’s combinatorial barcoding chemistry into its “Sample to Insight” portfolio, QIGEN aims to provide end‑to‑end solutions that support large‑scale cellular data generation and analysis, thereby reinforcing its position in the high‑growth single‑cell market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.